Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Speeding Up Peptide Mapping

In manufacturing biopharmaceuticals, companies must characterize the molecules to ensure efficacy and safety. For proteins, that characterization can be done with peptide mapping, which can be used to confirm the sequence of amino acids and reveal any post-tra

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

In manufacturing biopharmaceuticals, companies must characterize the molecules to ensure efficacy and safety. For proteins, that characterization can be done with peptide mapping, which can be used to confirm the sequence of amino acids and reveal any post-translational modifications (PTMs).

To do this, companies take a time-consuming approach to digest the proteins and then analyze the resulting peptides with reversed-phase chromatography, but Jonathan Bones, PhD, an analytical chemist at the National Institute for Bioprocessing Research and Training in Dublin, Ireland, and his colleagues described a faster method, which automates the digestion by using magnetic beads.

Three members of the Bones lab—Silvia Millán-Martín, Pharm D, Sara Carillo, PhD, and Craig Jakes—teamed up to field questions about this work. They note: “Peptide mapping analysis offers the advantage of providing site-specific information regarding post-translational and chemical modifications that may arise during production, processing, or storage.”

As these scientists point out, some “PTMs can negatively impact potency, immunogenicity, and stability.” The most challenging PTMs, they say, “are asparagine deamidation and aspartic acid isomerization and glycosylation, which may potentially cause a decrease in antigen binding affinity, resulting in loss of potency or impact immunogenicity.” The scientists add that, “oxidation occurs frequently with methionine and tryptophan residues and results in decreased thermal stability, increased aggregation potential, and thus an increased immunogenicity risk.”

These researchers showed that a simplified combination of automated sample digestion followed by analysis with LC-MS—specifically, high-resolution mass-accurate mass spectrometry, or HRAM MS—can track multiple PTMs and confirm the amino-acid sequence. Plus, they even tested the workflow in four independent labs to confirm that other scientists can implement this method consistently in the real world.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
Research context

Read sources and limitations before applying a claim.

Design notes for reproducible wellness studies

1) Define endpoints first. 2) Control light, sleep, feeding, and temperature. 3) Use pulse or block timing. 4) Track HRV and readiness scales. 5) Keep SOPs and batch records.

Source: puretestedpeptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →